These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. Geller BL; Deere J; Tilley L; Iversen PL J Antimicrob Chemother; 2005 Jun; 55(6):983-8. PubMed ID: 15872045 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of the proliferative effect of transforming growth factor-alpha by c-myc antisense DNA in human ovarian cancer cells. Park HY Biochem Mol Biol Int; 1997 Dec; 43(5):1015-22. PubMed ID: 9415810 [TBL] [Abstract][Full Text] [Related]
26. Perspectives on antisense therapy for the prevention of restenosis. Kipshidze N; Moses J; Shankar LR; Leon M Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351 [TBL] [Abstract][Full Text] [Related]
27. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression. Stewart DA; Xu X; Thomas SD; Miller DM Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846 [TBL] [Abstract][Full Text] [Related]
28. Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition. Saijo Y; Uchiyama B; Abe T; Satoh K; Nukiwa T Jpn J Cancer Res; 1997 Jan; 88(1):26-33. PubMed ID: 9045892 [TBL] [Abstract][Full Text] [Related]
29. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Arora V; Cate ML; Ghosh C; Iversen PL Drug Metab Dispos; 2002 Jul; 30(7):757-62. PubMed ID: 12065433 [TBL] [Abstract][Full Text] [Related]
30. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941 [TBL] [Abstract][Full Text] [Related]
31. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. Arora V; Knapp DC; Smith BL; Statdfield ML; Stein DA; Reddy MT; Weller DD; Iversen PL J Pharmacol Exp Ther; 2000 Mar; 292(3):921-8. PubMed ID: 10688605 [TBL] [Abstract][Full Text] [Related]
32. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice. Wickstrom E; Bacon TA; Wickstrom EL; Werking CM; Palmiter RD; Brinster RL; Sandgren EP Nucleic Acids Symp Ser; 1991; (24):151-4. PubMed ID: 1841270 [TBL] [Abstract][Full Text] [Related]
33. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line. Fei R; Shaoyang L Gynecol Oncol; 2002 Apr; 85(1):40-4. PubMed ID: 11925118 [TBL] [Abstract][Full Text] [Related]
34. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Fujimoto K; Takahashi M Biochem Biophys Res Commun; 1997 Dec; 241(3):775-81. PubMed ID: 9434785 [TBL] [Abstract][Full Text] [Related]
35. Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Inagaki M; Togawa K; Carr BI; Ghosh K; Cohen JS Transplant Proc; 1992 Dec; 24(6):2971-2. PubMed ID: 1334602 [TBL] [Abstract][Full Text] [Related]
36. Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides. Mandiyan S; Schumacher C; Cioffi C; Sharif H; Yuryev A; Lappe R; Monia B; Hanson S; Goff S; Wennogle L Antisense Nucleic Acid Drug Dev; 1997 Dec; 7(6):539-48. PubMed ID: 9450911 [TBL] [Abstract][Full Text] [Related]
37. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Sun L; Fuselier JA; Murphy WA; Coy DH Peptides; 2002 Sep; 23(9):1557-65. PubMed ID: 12217415 [TBL] [Abstract][Full Text] [Related]
38. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Knapp DC; Mata JE; Reddy MT; Devi GR; Iversen PL Anticancer Drugs; 2003 Jan; 14(1):39-47. PubMed ID: 12544257 [TBL] [Abstract][Full Text] [Related]
39. Enhanced in vivo tumour response from combination of carboplatin and low-dose c-myc antisense oligonucleotides. Walker TL; Dass CR; Burton MA Anticancer Res; 2002; 22(4):2237-45. PubMed ID: 12174909 [TBL] [Abstract][Full Text] [Related]
40. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells. Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]